OraSure decline creates long-term buying opportunity, says Barrington After OraSure reported weaker than expected Q3 results and provided weaker than expected Q4 guidance, Barrington expects the company to start rapidly penetrating the HCV and HIV markets. The firm maintains a $12.50 target and Outperform rating.
News For OSUR From The Last 14 Days
Check below for free stories on OSUR the last two weeks.
OraSure price target raised to $10 from $7.50 at Raymond James Raymond James raised OraSure's price target to $10 from $7.50 to reflect HCV and DNA Genotek drivers, accretive M&A, and disciplined spending. Shares are Outperform rated.